Measuring serum beta2-microglobulin to predict long-term mortality in hemodialysis patients using low-flux dialyzer reuse

This article was published in the following Dove Press journal:
Therapeutics and Clinical Risk Management

Nguyen Huu Dung¹
 Nguyen Trung Kien²
 Nguyen Thi Thu Hai¹
 Phan The Cuong¹
 Nguyen Thi Thu Huong³
 Dao Bui Quy Quyen⁴
 Nguyen Minh Tuan⁴
 Do Manh Ha²
 Truong Quy Kien²
 Nguyen Thi Thuy Dung²
 Pham Quoc Toan²
 Hoang Trung Vinh²
 Tomoko Usui⁵
 Le Viet Thang²

¹Bach Mai Hospital, Ha Noi, Vietnam;

²Military Hospital 103, Ha Noi, Vietnam;

³Ha Noi Kidney Hospital, Ha Noi, Vietnam;

⁴Cho Ray Hospital, Ho Chi Minh, Vietnam; ⁵University of Tokyo Hospital, Tokyo, Japan

Purpose: Beta2-microglobulin (β 2-M) is recognized as a surrogate marker relating to the mechanisms of dialysis-associated amyloidosis. Few studies have evaluated the association of serum β 2-M with clinical outcome in hemodialysis patients using high-flux type. However, study on patients using low-flux dialyzer reuse has not been done yet.

Patients and methods: Using serum β 2-M level on predicting long-term mortality of hemodialysis patients was examined in 326 prevalent hemodialysis patients (45.59 ± 14.46 years, hemodialysis duration of 47.5 (26–79) months, 186 males and 140 females). The patients were divided into 3 groups with equal number of patients, according to their serum β 2-M levels: group A ($n=109$, serum β 2-M concentration ≤ 55.7 mg/L), group B ($n=109$, serum β 2-M level from 55.8 mg/L to 75.4 mg/L) and group C ($n=108$, serum β 2-M concentration > 75.4 mg/L).

Results: During the follow-up period of 5 years, there were 75 all-cause deaths (23.0%). Kaplan–Meier analysis revealed that all-cause mortality in the higher β 2-M group was significantly higher compared to that in the lower β 2-M groups ($p < 0.001$). Serum β 2-M level was a significant predictor for all-cause mortality (AUC = 0.898; $p < 0.001$; Cut-off value: 74.9 mg/L, Se=93.3%, Sp=92.9%).

Conclusion: Serum β 2-M levels were a significant predictor of long-term mortality in hemodialysis patients, who use only low-flux dialyzers and reuse 6 times.

Keywords: Beta2-microglobulin, mortality, hemodialysis

Introduction

Beta2-microglobulin (β 2-M) is a middle-molecular-weight protein with 11,800 Dal, which is produced by all cells expressing the major histocompatibility class I. β 2-M is filtered by the glomerulus and is degenerated in the proximal tubules through a megalin-dependent pathway.¹ In patients with a reduced glomerular filtration rate, circulating β 2-M levels are elevated.¹ In dialysis patients, in whom the glomerular filtration rate is almost completely abolished, β 2-M accumulates in the circulation far above its levels in normal subjects and difficult to dialyze by use of low-flux membrane.² The deposition of β 2-microglobulin induced by reactive inflammation causing carpal tunnel syndrome is one of the complications of dialysis-related amyloidosis (DRA) in maintaining hemodialysis patients.³ In recent years, the role of β 2-M as a marker of cardiovascular and/or mortality risk has grown.^{4–6} Thus, removal of circulating β 2-M during hemodialysis has been considered to be beneficial. Several methods to reduce plasma β 2-M levels have been used in dialyzed

Correspondence: Le Viet Thang
 Department of Nephrology and
 Hemodialysis, Military Hospital 103,
 Vietnam Military Medical University, 261
 Phung Hung, Ha Dong, Ha Noi, Vietnam
 Tel +84 98 224 9968
 Email lethangviet@yahoo.co.uk

patients, such as the use of high-flux membrane,^{7–9} hemodiafiltration.^{10–13} Role of β 2-M in predicting outcome and mortality in both hemodialysis and peritoneal dialysis patients was published in few previous papers.^{14–16} In Vietnam, due to paucity of indigenous research, β 2-M levels in hemodialysis patients are not known. Hence, in this study, we examined the levels of serum β 2-M as well as the relationship between serum β 2-M and survival of hemodialysis patients in a single dialysis center, where low-flux membranes are used exclusively as a standard approach and the reuse of membranes is done at all.

Subjects and methods

Subjects

There were 514 patients on prevalent hemodialysis (hemodialysis duration >3 months) who joined in our study at Hemodialysis Center, Bach Mai Hospital, Hanoi, Vietnam, as of February 2011. Of these, patients with acute illness, significant infection, malignancy, or used high-flux dialyzer were excluded. The remaining patients, 326 prevalent hemodialysis patients, were provided informed consent prior to participation in our study. The enrolled patients were treated with stable, regular hemodialysis, using bicarbonate dialysate. Our dialysis program used low-flux membrane as a standard reuse of dialyzer. Kt/V was calculated according to the formula of Daugirdas.¹⁷ Each dialysis session was between 3.5 and 4.5 hrs, in order to achieve the target total Kt/V of around 1.2 per session for three times weekly treatment. Reuse of dialyzer was performed for 6 times in all patients. The clinical diagnoses of primary renal disease were chronic glomerulonephritis, hypertensive nephropathy, chronic pyelo-nephritis, diabetic nephropathy, polycystic kidney disease, gout.

The clinical diagnoses of pain of shoulder, carpal tunnel syndrome were performed. Number of died patients with all-causes was collected during 5 years.

To achieve the goal that whether serum β 2-M as marker predicting mortality, we arranged 326 patients in increasing order of concentration. The patients were divided into 3 groups with equal number of patients, according to the concentration of serum β 2-M: group A with 109 patients (serum β 2-M concentration ≤ 55.7 mg/L), group B with 109 patients (serum β 2-M level from 55.8 mg/L to 75.4 mg/L) and group C with 108 patients (serum β 2-M concentration >75.4 mg/L).

Also, this study was approved by the ethics review committee of the hospital.

Biochemical assays and other measurements

Blood was drawn just before the start of a dialysis session in a non-fasting state, to measure serum albumin, creatinine, blood urea nitrogen, C-reactive protein (CRP) and hematocrit, using routine laboratory methods, one a month as a routine clinical care as performed in most dialysis facilities in Vietnam. Serum β 2-M concentration was measured using latex immunoassay principle at the time of enrolment.

Statistical methods

All the continuous data were represented by mean and standard deviation and were analyzed by ANOVA and Student *t*-test. Categorical data were presented by frequency with percentage and were analyzed using Chi-square test. Receiver operating characteristic (ROC) curves with the area under the curve (AUC) was calculated to predict mortality from patients after 5 years follow-up. Multivariate regression analysis was performed to identify the predictors of hospital mortality. Survival curves were assessed using the Kaplan–Meier analysis and evaluated by the log-rank test. Statistical analysis was done using Statistical Package for Social Science (SPSS) version 20.0 (Chicago, IL, USA). A *p*-value < 0.05 was considered as significant.

Results

The baseline demographic and laboratory characteristics in patients are shown in Table 1. In our study, we found no difference in age, sex, BMI, rate of hypertension, causes of chronic renal failure, serum creatinine, serum albumin, hemoglobin level and anemia rate in groups A, B and C.

However, the results of our study showed that in patient group with higher serum β 2-M, there was a long duration of hemodialysis, the rate of shoulder pain, tunnel syndrome, hepatitis virus infection, and especially the rate mortality was higher than in patients with lower serum β 2-M concentrations, *p* < 0.001.

In addition, patients with higher serum β 2-M concentrations had a lower proportion of patients with residual renal function and higher median hs-CRP levels than patients with lower serum β 2-M level, *p* < 0.001.

There was a positive correlation, moderate level of serum β 2-M concentration with duration of hemodialysis and serum hs-CRP concentration, correlation coefficients of 0.641; 0.506, respectively, *p* < 0.001 (Table 2).

Table 1 Clinical characteristics and laboratory parameters of the studied patients (n=326)

	Total (n=326)	Group A ($\beta 2\text{-M} \leq 55.7$ mg/L), (n=109)	Group B ($\beta 2\text{-M}$ from 55.8–75.4 mg/L), (n=109)	Group C ($\beta 2\text{-M} > 75.4$ mg/L), (n=108)	P for trend
Ages (years)	45.59±14.46	45.39±14.56	46.64±15.5	44.73±13.29	0.614
Male, n (%)	186 (57.1)	66 (60.6)	60 (55)	60 (55.6)	0.663
Duration of hemodialysis (month)	47.5 (26–79)	28 (16–40)	53 (27–73)	81 (53.25–108.75)	<0.001
BMI	19.17±2.35	19.18±2.59	19.17±2.05	19.17±2.41	0.998
Hypertension, n (%)	244 (74.8)	83 (76.1)	79 (72.5)	82 (75.9)	0.783
Pain of shoulder, n (%)	102 (31.3)	16 (14.7)	36 (33)	50 (46.3)	<0.001
Carpal tunnel syndrome, n (%)	40 (12.3)	4 (3.7)	10 (9.2)	36 (24.1)	<0.001
Etiology, n (%)					0.063
• CGN	230 (70.6)	88 (80.7)	67 (61.5)	75 (69.4)	
• Chronic pyelonephritis	43 (13.2)	10 (9.2)	19 (17.4)	14 (13)	
• Diabetic nephropathy	32 (9.8)	9 (8.3)	13 (11.9)	10 (9.3)	
• Others	21 (6.4)	2 (1.8)	10 (9.2)	9 (8.3)	
Residual kidney function, n(%)	63 (19.3)	39 (35.8)	16 (14.7)	8 (7.4)	<0.001
HBV and/or HCV (+), n (%)	140 (42.9)	25 (22.9)	38 (34.9)	77 (71.3)	<0.001
Lipid disorder, n (%)	213 (65.3)	58 (53.2)	76 (69.7)	79 (73.1)	0.004
Urea (mmol/L)	28.8 (25.1–33.9)	27.4 (24–31.2)	28.2 (24.95–32.7)	30.9 (26.4–37.5)	<0.001
Creatinine ($\mu\text{mol/L}$)	824 (656.5–986)	824 (666–982)	837 (666.5–987)	824 (643–978.5)	0.954
Albumin (g/L)	38.71±3.56	38.73±3.1	39.16±3.96	38.24±3.56	0.168
Hs-CRP (mg/L)	0.4 (0.1–0.7)	0.2 (0.1–0.3)	0.4 (0.2–0.6)	0.6 (0.4–1.17)	<0.001
Hemoglobin (g/L)	103.19±18.32	101.5±18.59	105.78±16.97	102.28±19.22	0.185
Anemia, n (%)	271 (83.1)	93 (85.3)	89 (81.7)	89 (82.4)	0.747
$\beta 2\text{-M}$ (mg/L)	66.75 (48.42–81.05)	40.4 (32.7–48.55)	66.8 (61.2–71.6)	85.4 (81.05–92.17)	<0.001
Mortality for all causes, n (%)	75 (23.0)	3 (2.8)	4 (3.7)	68 (63)	<0.001

Abbreviations: BMI, Body Mass Index; CGN, Chronic Glomerulonephritis; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; hs-CRP, high sensitive C Reactive Protein.

Table 2 Correlation between serum $\beta 2$ -M level and duration and hs-CRP

Variables	$\beta 2$ -M (mg/L)		Correlation equation
	r	p	
Duration of hemodialysis	0.641	<0.001*	$\beta 2$ -M = 0.359*Duration of hemodialysis + 44.43
Serum hs-CRP (mg/L)	0.506	<0.001*	$\beta 2$ -M = 23.14*hs-CRP + 52.97

Note: *Statistical significance.

Abbreviation: Hs-CRP: high sensitive C Reactive Protein.

Using multivariate logistic regression analysis, hemodialysis patients with long duration of hemodialysis and serum $\beta 2$ -M were independent risk factors for long-term mortality (Table 3).

Using ROC curve model to predict mortality in maintenance hemodialysis patients for 5 years, we realized that serum $\beta 2$ -M concentration has an equal predictive value of mortality compared with hemodialysis duration and had a better predictive value than renal residual function (Figure 1).

The Kaplan–Meier analysis model showed that patients with higher $\beta 2$ -M concentrations had a significant higher death rate than those with lower $\beta 2$ -M concentrations (Figure 2).

Discussion

Level of serum $\beta 2$ -M hemodialysis patients

Our results show that 100% of patients had elevated serum concentrations of $\beta 2$ -M compared to that of normal people (normal value <3 mg/L). Median $\beta 2$ -M level of serum was 66.75 mg/L (Table 1). There were many studies in the world that reported serum $\beta 2$ -M concentrations in patients with chronic renal failure treating with maintaining hemodialysis. In 1999, Dixit MP et al¹⁸ studied levels of serum

$\beta 2$ -M in 30 young dialysis patients (mean age was 18.7 $\pm$ 0.9 years old) who used cellulose membrane dialyzer; the result showed that level of serum $\beta 2$ -M was 49.7 $\pm$ 3.9 mg/L. Okuno S et al¹⁵ studied serum $\beta 2$ -M levels in 490 dialysis patients, with an average age of 60.1 years, mean dialysis duration was 87.4 months. The patients were treated with high-flux dialyzers; that is, reuse not done at all. The results show that mean level of serum $\beta 2$ -M was 32.2 mg/L. The study by Mumtaz A et al¹⁹ in 50 patients use low-flux dialyzer; the concentration of $\beta 2$ -M was 92.6 mg/L. The level of serum $\beta 2$ -M in study of Traut et al²⁰ in 20 patients using low-flux dialyzer was 42.0 mg/L. Thus, increase of serum $\beta 2$ -M was common in chronic renal failure patients treated with maintaining hemodialysis. However, the increase of serum $\beta 2$ -M concentrations in each study was different, suggesting that the serum $\beta 2$ -M concentration in hemodialysis depends on many patient characteristics. First, residual kidney function is related to serum $\beta 2$ -M levels in this patient group. Beta 2-microglobulin is found on the surface of all nucleated cells and plays a central role in cellular immunology. Its synthesis rate normally ranges from 2 to 4 mg/kg/day with a half life of 2–5 hrs.¹ In healthy individuals, the plasma concentration varies from 1 to 3 mg/L, which varies inversely with the glomerular filtration rate. More

Table 3 Result of multivariate logistic regression analysis showing predictors of hospital mortality of hemodialysis patients after 5 years

Variable	Adjusted hazard ratio	95% CI	p
Age	0.994	0.963–1.026	0.709
Sex: male	1.204	0.522–2.777	0.664
Duration of hemodialysis	1.037	1.022–1.051	<0.001*
HBV and/or HCV (+)	1.992	0.86–4.616	0.108
Albumin	0.898	0.801–1.007	0.066
Serum hs-CRP (mg/L)	0.433	0.157–1.193	0.106
Hemoglobin (g/l)	0.996	0.977–1.016	0.726
$\beta 2$ -M (mg/L)	1.093	1.052–1.135	<0.001*

Note: *Statistical significance.

Abbreviations: HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; hs-CRP, high sensitive C Reactive Protein.

Figure 1 Receiver operating characteristics (ROC) curves of serum β 2-M, hemodialysis duration and residual kidney function for prediction of hospital mortality of hemodialysis patients with all-causes. β 2-M: AUC =0.898; $p<0.001$; Cut-off value: 74.9 mg/L, Se=93.3%, Sp=92.9%. Hemodialysis duration: AUC =0.907; $p<0.001$; Cut-off value: 63 months, Se=96%, Sp=78.9%. Urine 24 hrs volume: AUC =0.669; $p<0.001$; Cut-off value: 225 mL, Se=93.3%, Sp=38.2%. Serum β 2-M concentration has an equal predictive value of mortality compared with hemodialysis duration and had a better predictive value than renal residual function in maintenance hemodialysis patients for 5 years.

Figure 2 Kaplan–Meier analysis of all-causes mortality of 326 hemodialysis patients, classified according to β 2-M concentrations in 3 groups A, B and C. Patients with higher β 2-M concentrations (red line – group C) exhibited a significantly higher death rate compared to those with lower serum β 2-M concentrations (blue line – group B and violet line – group A) (log-rank test, $p<0.001$).

than 95% of β 2-M is eliminated by degradation in the proximal tubule. Since this compound cannot be removed from the serum by the kidney or certain dialysis membranes in patients with renal dysfunction on dialysis, β 2-M concentration is increased by up to 60-fold in patients with end-stage renal disease.¹ In patients with remaining residual kidney function, level of serum β 2-M will be lower than that of the patients without residual kidney function,

because an amount of serum β 2-M will still be excreted by the kidney in dialysis patients. Results of our study also show this in Table 1: In patients with higher serum β 2-M concentration, the proportion of patients still having residual renal function was lower (groups A, B, C: 35.8%, 14.7% and 7.4%, respectively), $p<0.001$.

The major reason for such a high level of β 2-M in this study was that the dialyzer used for hemodialysis in our patients was of the low-flux dialyzer for a long time. As β 2-M is a middle molecule of molecular weight, conventional, low-flux dialyzers do not clear these molecules which lead to accumulation of this silent killer in the body. Financial constraints are the major reason for using low-flux dialyzers in our patients. The same group of dialysis patients, but in our study of Okuno S et al,¹⁵ show that β 2-M levels were lower (32.3 mg/L versus 64.74 mg/L) while our dialysis time was lower (87.4 months versus 47.5 months). The role of high-flux types in decreasing serum β 2-M level has been published by some authors.^{7,21,22} In addition, long-term dialysis is also a cause of elevated serum β 2-M concentrations (results are shown in Tables 1 and 2).

In Vietnam, the number of patients with end-stage chronic kidney disease is increasing, due to complications of diabetes and hypertension. Hemodialysis is still a major treatment for end-stage renal disease patients. Patients receive dialysis three times a week, 3.5 hrs to 4 hrs per time. However, patients must re-use the dialyzers 6 times. The washing, soaking, sterilizing dialyzers were done following strictly compliant with the

standards of the Vietnam Ministry of Health. Although the quality of dialysis with re-used dialyzers is safe, the potential for infection with hepatitis virus and other infection is present in dialysis patients. This is evident in Table 1, with 42.9% of patients infected with hepatitis B/C virus in our study. Patients with high β 2-M levels had a higher prevalence of hepatitis virus infection than those with lower β 2-M level (Ratio of hepatitis virus infection in groups A, B, C: 22.9%, 34.9% and 71.3%, respectively), $p < 0.001$. Especially in patients with higher β 2-M levels, the median value of CRP-hs was higher than that of lower β 2-M group (0.6 mg/L versus 0.4 mg/L versus 0.2 mg/L), $p < 0.001$. β 2-M is accumulated in the circulation of dialysis patients and its role on immunity and inflammation has been already reported.²³ The results of our study also showed the relationship (Tables 1 and 2). Dialysis treatment per se has been considered to be an inflammatory stimulus, inducing cytokine production (such as interleukin-1, tumor necrosis factor- α , interleukin-6) and complement activation. The released cytokines are thought to stimulate the synthesis and release of β 2-M by the macrophages and/or augment the expression of human leukocyte antigens (class I), increasing β 2-M expression. Based on the findings of previous studies and our study, we could support that the elevated β 2-M serum concentrations predispose to an up-regulation of the inflammatory procedure in dialysis patients.

DRA is a serious complication of long-term dialysis therapy and is characterized by the deposition of amyloid fibrils, principally composed of β 2-M, in the osteoarticular structures and viscera. The duration on hemodialysis treatment plays an important role in the development of DRA.^{24–26} Carpal tunnel syndrome and pain of shoulder are two of the clinical manifestations of the DRA. Numerous studies have also demonstrated the role of β 2-M in the pathogenesis of DRA and related clinical manifestations of carpal tunnel syndrome and pain of shoulder in maintaining dialysis patients.^{2,27} Our results also show that the ratio of patients with carpal tunnel syndrome and/or pain of shoulder in group with high β 2-M levels were significantly higher than those of group with low β 2-M levels, $p < 0.001$ (Table 1).

Predictive value of mortality of serum β 2-M

Although there were 514 patients in our dialysis center, however, only 326 patients met the criteria chosen in this study: patients who had had dialysis at the center for >3 months, using low-flux dialyzer with reuse 6 times, were monitored continuously for 5 years. In 5 years of follow-up, from February 2011 to February 2016, up to 75 patients died from all causes, accounting for 23%

(Table 1). Multiple regression analysis revealed that duration of dialysis and serum β 2-M levels were independent risk factors predicting of death in 5 years in this study (Table 3). In particular, serum β 2-M level ≥ 74.9 mg/L was also an independent predictor of mortality in our study group (AUC = 0.898; $p < 0.001$; Se = 93.3%, Sp = 92.9%). Compared with hemodialysis duration and residual kidney function, serum β 2-M concentration had an equal predictive value of mortality compared with hemodialysis duration and had a better predictive value than renal residual function in maintenance of hemodialysis patients for 5 years (Figure 1).

In Vietnam, although many studies have been conducted in patients with end-stage renal disease, treatment with maintaining dialysis, however, no studies have been done to assess the role of serum β 2-M in the predicting mortality in dialysis patients. Kaplan–Meier analysis was performed to examine the univariate association between the 3 groups based on the β 2-M concentrations and the outcomes of the cohort (Figure 2). Patients with higher β 2-M concentrations exhibited a significantly higher death rate than those with lower β 2-M concentrations (log-rank test, $p < 0.001$).

In the world, there were some studies referring to this issue. In 2006, Cheung AK et al¹⁴ in the HEMO study reported that the pre-dialysis serum β 2-M level predicted mortality. In 2009, Okuno S et al¹⁵ confirmed that β 2-M level at cut-off 32.2 mg/L, predicting mortality in dialysis patients, who follow-up for 50 months. When comparing the cut-off point for β 2-M level predicting mortality in dialysis patients, we found that the study of Okuno S et al can predict with the lowest β 2-M level, followed by Chung, while our study predicting with the highest β 2-M level. This difference can be explained by the fact that Okuno's subjects are patients who use high-flux dialyzer, and Cheung's subjects are patients who use both low-flux and high-flux types, but our patients use only low-flux dialyzers.

Although studies have shown that serum β 2-M level has a value predicting mortality in dialysis patients, however, in clinical practice there are many well-known factors such as cardiovascular events, hemodialysis effect, malnutrition which also have this value.

Conclusion

In conclusion, we demonstrated that serum β 2-M levels were a significant predictor of mortality in hemodialysis patients, who use only low-flux dialyzers and reuse 6 times with relatively longer hemodialysis durations of 47.5 (26–79) months.

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Vietnam Military Medical University (No.2134/QĐ/HVQY). All patients provided written informed consent.

Human and animal rights

Animals were not used in this research. All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2008.

Acknowledgments

In this study, we had been strongly supported by clinical application funding of our local hospital and university to complete our research.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. *Kidney Int.* 1987;32(5):635–641.
2. Scarpioni R, Ricardi M, Albertazzi V, et al. Dialysis-related amyloidosis: challenges and solutions. *Int J Nephrol Renovasc Dis.* 2016;9:319–328. doi:10.2147/IJNRD.S84784
3. Weng CH, Hu CC, Yen TH, et al. Association between environmental particulate matter and carpal tunnel syndrome in patients undergoing hemodialysis. *Kidney Blood Press Res.* 2017;42(5):827–836. doi:10.1159/000484422
4. Zumrutdal A. Role of β 2-microglobulin in uremic patients may be greater than originally suspected. *World J Nephrol.* 2015;4(1):98–104. doi:10.5527/wjn.v4.i1.98
5. Liabeuf S, Lenglet A, Desjardins L, et al. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. *Kidney Int.* 2012;82(12):1297–1303. doi:10.1038/ki.2012.301
6. Sedighi O, Abediankenari S, Omranifar B. Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease. *Nephrourol Mon.* 2014;7(1):e23563. doi:10.5812/numonthly
7. Argyropoulos C, Roumelioti ME, Sattar A, et al. Dialyzer reuse and outcomes of high flux dialysis. *PLoS One.* 2015;10(6):e0129575. doi:10.1371/journal.pone.0129575
8. Topçiu-Shufta V, Miftari R, Haxhibeqiri V, et al. Association of Beta-2 microglobulin with inflammation and dyslipidemia in high-flux membrane hemodialysis patients. *Med Arch.* 2016;70(5):348–350. doi:10.5455/medarch.2016.70.348-350
9. Donadio C, Tognotti D, Caponi L, et al. β -trace protein is highly removed during haemodialysis with high-flux and super high-flux membranes. *BMC Nephrol.* 2017;18(1):68. doi:10.1186/s12882-017-0489-6
10. Maduell F, Sánchez-Canel JJ, Blasco JA, et al. [Middle molecules removal. Beyond beta2-microglobulin]. *Nefrologia.* 2006;26(4):469–475.
11. Penne EL, van der Weerd NC, Blankestijn PJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. *Clin J Am Soc Nephrol.* 2010;1(1):80–86. doi:10.2215/CJN.03340509
12. Sakurai K. Biomarkers for evaluation of clinical outcomes of hemodiafiltration. *Blood Purif.* 2013;35(Suppl 1):64–68. doi:10.1159/000346364
13. Jean G, Hurot JM, Deleaval P, et al. Online-haemodiafiltration vs. conventional haemodialysis: a cross-over study. *BMC Nephrol.* 2015;16:70. doi:10.1186/s12882-015-0062-0
14. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. *J Am Soc Nephrol.* 2006;17:546–555. doi:10.1681/ASN.2005020132
15. Okuno S, Ishimura E, Kohno K, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. *Nephrol Dial Transplant.* 2009;24(2):571–577. doi:10.1093/ndt/gfn521
16. Koh ES, Lee K, Kim SH, et al. Serum β 2-microglobulin predicts mortality in peritoneal dialysis patients: a prospective cohort study. *Am J Nephrol.* 2015;42(2):91–98. doi:10.1159/000439060
17. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. *J Am Soc Nephrol.* 1993;4:1205–1213.
18. Dixit MP, Cabansag MR, Piscitelli J, et al. Serum beta2-microglobulin and immunoglobulin levels in young hemodialysis patients. *Pediatr Nephrol.* 1999;13(2):139–142.
19. Mumtaz A, Anees M, Bilal M, et al. Beta-2 microglobulin levels in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2010;21(4):701–706.
20. Traut M, Haufe CC, Eismann U, et al. Increased binding of Beta-2 microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced Beta2-microglobulin concentrations. *Blood Purif.* 2007;25:432–440. doi:10.1159/000110069
21. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med.* 2002;347(25):2010–2019. doi:10.1056/NEJMoa021583
22. Kim HW, Kim SH, Kim YO, et al. Comparison of the impact of high-flux dialysis on mortality in hemodialysis patients with and without residual renal function. *PLoS One.* 2014;9(6):e97184. doi:10.1371/journal.pone.0097184
23. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. *Circulation.* 2005;112:976–983. doi:10.1161/CirculationNaha.104.513085
24. Al-Taei IK, Al-Safar JJ, Al-Falahi YS, Al-Shamma IA. The clinical significance of β 2-microglobulin in end-stage renal disease. *Saudi J Kidney Dis Transpl.* 2003;14(4):492–496.
25. Celik G, Capraz I, Yontem M, et al. The relationship between the antioxidant system, oxidative stress and dialysis-related amyloidosis in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2013;24(6):1157–1164. doi:10.4103/1319-2442.121272
26. Tsai TT, Kaliya-Perumal AK, Jenq CC, et al. The unresolved problem of beta-2 microglobulin amyloid deposits in the intervertebral discs of long-term dialysis patients. *J Orthop Surg Res.* 2017;12(1):194. doi:10.1186/s13018-017-0697-6
27. Shin J, Nishioka M, Shinko S, et al. Carpal tunnel syndrome and plasma beta2-microglobulin concentration in hemodialysis patients. *Ther Apher Dial.* 2008;12(1):62–66. doi:10.1111/j.1744-9987.2007.00542.x

Therapeutics and Clinical Risk Management

Dovepress

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS,

EMBASE, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>